Delphia (USA)’s Intellia Therapeutics NTLA Stock Holding History

Delphia (USA)’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,238	Closed	-$219K	–	378
2022 Q2	$219K	Buy	+4,238	New	+$215K	0.15%	260

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Delphia (USA)'s NTLA Position: Q3 2022 in Review

Delphia (USA) sold out of Intellia Therapeutics (NTLA) in Q3 2022, closing a stake of 4,238 shares — an estimated $219K sold.

Delphia (USA) first reported a position in NTLA in Q2 2022 and held it in 1 quarter. The position peaked at $219K in Q2 2022. 319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

Delphia (USA) reported no remaining Intellia Therapeutics position as of Q3 2022 after selling out during the quarter.
Delphia (USA) sold 4,238 Intellia Therapeutics shares in Q3 2022, an estimated $219K.
Delphia (USA) first reported a position in Intellia Therapeutics in Q2 2022 and held it in 1 quarter.
Delphia (USA)'s Intellia Therapeutics position peaked at $219K in Q2 2022.
319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.